2nd April 2024
Our new Director Professor Nitzan Rosenfeld tells us about his journey leading to the BCI.
Read more15th February 2024
The ATOMIC-meso trial is the culmination of 20 years of research at the Barts Cancer Institute
Read more6th December 2021
Recent research from Barts Cancer Institute (BCI) at Queen Mary University of London has identified a novel therapeutic strategy to target lung cancer tumours that lack the gene LIMD1. We spoke with Professor Tyson V Sharp from BCI’s Centre for Cancer Cell & Molecular Biology, who led the study with Dr Sarah Martin, to find out more about the research and the significance of the findings.
Read more16th September 2020
Results from a phase I clinical trial led by Professor Peter Szlosarek were recently published in JTO Clinical and Research Reports. The trial was investigating the safety and efficacy of a new drug combination for the treatment of mesothelioma. We spoke to Professor Szlosarek to find out more about the trial, and how the drug combination may be able to help patients with mesothelioma.
Read more30th November 2018
November is Lung Cancer Awareness Month. Lung cancer is one of the main cancer types on which research is focused here at the Barts CRUK Centre.
Read more7th August 2018
A new study performed by researchers from BCI led by Dr Tyson Sharp, Lead of the Centre for Molecular Oncology, has identified a novel mechanism implicated in the development of lung adenocarcinoma (the most common type of non-small cell lung cancer), mediated by the loss of a gene called LIMD1.
Read more